CHRONIX BIOMEDICAL, INC
Chronix Biomedical, Inc.
is a molecular diagnostics company creating laboratory developed blood
tests, that are designed for therapy monitoring for patients with
chemotherapy or immunotherapy and for relapse monitoring after tumor
resection.
All Chronix tests are blood tests (Liquid biopsy tests) which detect tumor-derived cell-free DNA in blood samples of patients. Gains and losses of large chromosome sections that are present in the genome of cancer cells are detected and combined in a comprehensive copy number instability (CNI) score that can indicate tumor existance, remission or progression. Chronix blood tests are suitable for therapy monitoring for patients with chemotherapy or immunotherapy and for relapse monitoring after tumor resection (CNI MONITOR).
CNI score based predictions of a therapy failure were correct in 89% of times (positive predictive value, PPV) when based on the change from baseline to cycle 2. When data from another sample obtained prior to cycle 3 was included the prediction of progressive disease was correct in 100% of the cases.CHRONIX NEWS
Early detection of cancer – why is it important?
The number of people diagnosed with tumors, especially malignant ones, […]
It was the 5th year that Chronix Biomedical has been present at ASCO Annual Meeting in Chicago
This was the busiest ASCO conference yet for Chronix Biomedical. Chronix booth was visited by clinical trial oncologists, international cancer research...
Chronix Biomedical reports positive interim pancreatic cancer data
Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.
Chronix Biomedical presents positive data on prognostic test in head/neck cancer study data at ASCO
Study finds CNI score to be a stronger predictor of time to recurrence in head and neck cancer than current method based on lymph node invasion. The study enrolled 54 patients undergoing surgery for this cancer type and evaluated the Chronix test as a predictor of time to progression in comparison with the current method based on the degree of tumour invasion of lymph nodes (pN status).
Chronix Biomedical is pleased to be a sponsor of the PCRT annual meeting
Chronix Biomedical
Chronix looks forward to working with this team of international pancreatic cancer experts.
Chronix at the ASCO 2017 Annual Meeting
Chronix Biomedical
This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.
VIDEOS
Madappa N. Kundranda, MD, PhD. Director, Gastrointestinal Oncology Program, Adjunct Assistant Professor, University of Texas MD Anderson Cancer Center, Banner MD Anderson, Arizona.
Experts on Chronix Biomedical CNI Monitor test. Testing for drug […]
Chronix ASCO 2017: Dr Glen Weiss
Experts on Chronix Biomedical CNI Monitor test. Testing for drug […]
Chronix ASCO 2017: Dr Tomislav Dragovich
Experts on Chronix Biomedical CNI Monitor test. Testing for drug […]
EVENTS
It was the 5th year that Chronix Biomedical has been present at ASCO Annual Meeting in Chicago
This was the busiest ASCO conference yet for Chronix Biomedical. Chronix booth was visited by clinical trial oncologists, international cancer research...
ORDER TESTS
DOCTORS ABOUT OUR TESTS
“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”